UNASSIGNED: 374 Background: It remains unclear whether @entity4381 (ZOL) improves @entity1349 ( @entity1349 ) for @entity1358 ( @entity1358 ) @entity1 with bone metastases. We retrospectively investigated the clinical benefit of ZOL for @entity1349 in @entity1358 @entity1 with bone metastases. METHODS: Between 1978 and 2010, 77 @entity1 who had @entity1358 metastatic to bone were treated in our hospital. Of them, 36 were treated with ZOL and their @entity1349 was significantly better than that of the other 41 @entity1 (1- and 3-year survival, 84% and 73% vs. 49% and 27%, respectively, p < 0.001). @entity1349 rates were clearly discriminated according to MSKCC model stratification: 3-year survival rates in the favorable, intermediate and poor risk groups were 83% (n = 12), 49% (n = 45), and 19% (n = 20), respectively (p=0.0033). To match characteristics in our retrospective study, we selected 45 @entity1 conforming to MSKCC intermediate risk group criterion. In this cohort, 23 @entity1 received ZOL (ZOL-treated group) whereas the other 22 did not (non-ZOL-treated group). The primary endpoint was @entity1349 and the secondary endpoint was the skeletal-related event (SRE) rate defined as the total number of SREs divided by the total years on study. RESULTS: For the cohort of 45 @entity1 , the median @entity1349 from diagnosis of bone metastases was 27.2 months. Multivariate analysis showed that low serum @entity460 (hazard ratio [HR]: 2.58, 95% confidence interval [CI]: 1.31 to 4.69; p = 0.0083) and ZOL treatment (HR: 1.89, 95% CI: 1.27 to 2.96; p = 0.0013) were independent factors predicting longer survival. The ZOL-treated group had significantly longer @entity1349 (1-year survival: 80.8%) than the non-ZOL-treated group (1-year survival: 59.1%, p = 0.0034). A difference in @entity1349 between the two groups still was present (p = 0.012) when the duration of molecular-targeted therapy was excluded from the @entity1349 period. @entity1 in the ZOL-treated group experienced a lower SRE rate (0.87/year) than @entity1 in the non-ZOL-treated group (1.82/year, p = 0.0453). In particular, none of the @entity1 in the ZOL-treated group developed spinal compression whereas 6 (28%) in the non-ZOL-treated group did (p = 0.0479). CONCLUSIONS: The current study indicates that ZOL not only reduces SREs but possibly improves @entity1349 in these @entity1 .

Significance of @entity4381 on survival in XXXX with bone metastases from @entity1358 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell carcinoma', 'RCC'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium'] @entity4381 :: ('MESH:C088658', 'Chemical') :: ['zoledronic acid'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity1 :: (9606,Species) :: ['patients']
